99mTc-帕米膦酸盐的制备及骨分布

doi:10.7538/tws.2016.29.01.0006

摘要/Abstract

摘要：

为观察^99mTc标记的帕米膦酸盐（Pamidronate，PAM）的骨分布特点，以氯化亚锡为还原剂，优化^99mTc直接标记PAM的条件，研究SnCl₂（Ⅱ）含量、配体用量、pH及反应时间对标记率的影响，确定了优化的标记条件；考察^99mTc-PAM的体外稳定性；评价^99mTc-PAM在正常鼠体内的生物分布，尤其是骨摄取情况，比较^99mTc-PAM与^99mTc-MDP在正常小鼠体内的骨摄取。实验结果表明，PAM的^99mTc标记方法简单，标记率大于95%，标记物体外稳定性好。正常鼠体内分布实验发现，^99mTc-PAM骨摄取很高，且滞留时间长，在血液中清除快，在体内主要通过肾代谢；正常大鼠SPECT显像骨组织清晰可见，具有很好骨显像效果。与^99mTc-MDP在正常小鼠体内的生物分布结果比较表明，^99mTc-PAM的骨放射性摄取及骨与血放射性摄取比在不同时相均优于^99mTc-MDP。研究表明，^99mTc-PAM具有理想的骨显像性能，可用于骨显像、骨损伤探测以及肿瘤骨转移检测等应用研究。

关键词: 骨显像剂, ^99mTc-帕米膦酸盐, 生物分布, SPECT显像, ^99mTc-亚甲基二膦酸盐

Abstract:

Labeling of Pamidronate (PAM) with ^99mTc was studied by a direct labeling method in the presence of SnCl₂•2H₂O as reducing agent. The influences of the concentration of SnCl₂•2H₂O, PAM concentration and pH value, reaction time on labeling yield were investigated. The optimum labeling was determined. The results showed that the radiochemistry purity of ^99mTc-PAM was more than 95%. Biodistribution studies in normal mice and rats showed very high uptake of ^99mTc-PAM and long retain in bone. ^99mTc-PAM was washed out from the blood very quickly. In addition, considerable uptake in the kidneys indicated this complex was excreted mainly by renal pathway. On the other hand, the radioactivity in liver, lung and heart was negligible. It could be known from SPECT images that ^99mTc-PAM would be an excellent bone-imaging agent. Bone uptake of ^99mTc-PAM was higher than that of ^99mTc-MDP in mice. This study suggested that ^99mTc-PAM was a promising bone imaging agent and further study was worthwhile.

Key words: bone imaging agent, ^99mTc-PAM, biodistribution, SPECT imaging, ^99mTc-MDP

罗洪义;沈浪涛;梁积新;杨春慧;张文辉;秦少鹏;卫成军;刘海春;王建华;李洪玉. ^99mTc-帕米膦酸盐的制备及骨分布[J]. 同位素, 2016, 29(1): 6-11.

LUO Hong-yi;SHEN Lang-Tao;LIANG Ji-xin;YANG Chun-hui;ZHANG Wen-Hui;QIN Shao-peng;WEI Cheng-jun;LIU Hai-Chun;WANG Jian-Hua;LI Hong-yu. Preparation and Biodistribution of ^99mTc-Pamidronate as Bone Imaging Agent[J]. Journal of Isotopes, 2016, 29(1): 6-11.

参考文献

［1］Subramanian G, Mcafee J G, Blair R J, et al. Technetium-99m-methylene diphosphonate a superior agent for skeletal imaging: comparison with other technetium complexes［J］. Journal of Nuclear Medicine, 1975, 16(8): 744-755.
［2］郭海波,孙达. ^99mTc-MDP骨显像时正常和异常的骨外放射性聚集［J］. 同位素,2011,24(4):246-251.Guo Haibo, Sun Da. Normal and abnormal extraosseous uptake of ^99mTc-MDP on bone scintigraphy［J］. Journal of Isotopes, 2011, 24(4): 246-251（in Chinese）.
［3］张树成,畅志华,刘巍. 帕米磷酸二钠(博宁)的特性及临床应用［J］. 河北医药,2004,26(1):75-76. ZHang Shucheng, CHang Zhihua, LIU Wei. The characteristics and clinical application of Pamidronate Disodium (Bonin)［J］. Hebei Medical Journal, 2004, 26(1): 75-76（in Chinese）.
［4］Kieczykowski G R, Jobson R B, Melillo D G, et al. Preparation of (4-amino-1-hydroxybutylidene) bisphosphonic acid sodium salt, MK-217 (alendronate sodium). An improved procedure for the preparation of 1-hydroxy-1, 1-bisphosphonic acids［J］. Journal of Organic Chemistry, 1995, 60(25): 8310-8312.
［5］Palma E, Correia Joa o D G, Campello M P C, et al. Bisphosphonates as radionuclide carriers for imaging or systemic therapy［J］. Molecular Biosystems, 2011, 7: 2950-2966.
［6］Kumar D, Kumar V, David G, et al. Evaluation of biodistribution by local versus systemic administration of ^99mTc-labeled pamidronate［J］. Journal of Orthpaedic Science, 2006, 11: 512-520.
［7］Kumar V, Howman G, Robert B, et al. Is ^99mTc-labeled pamidronate a better agent than ^99mTc-medronate for bone imaging？［J］. Nuclear Medicine Communications, 2007, 28(2): 101-107.
［8］杨南萍,左川,陈永涛,等. ⁹⁹Tc-亚甲基二膦酸盐注射液的临床新应用［J］. 中华风湿病学杂志,2003,7（12）:752-754.Yang Nanping, Zuo Chuan, CHen Yongtao, et al. Clinical application in the therapy of rheumatoid arthritis ^99mTc methylenediphosphona-te injection［J］. Chinese Journal Rheumatol, 2003, 7（12）: 752-754（in Chinese）.
［9］李心欣,李成浩. ⁹⁹锝-亚甲基二膦酸盐在类风湿性关节炎中的应用［J］. 实用药物与临床,2010,13（1）:69-70.Li Xinxin, Li Chenghao. Application of ⁹⁹Tc-MDP in the rheumatoid arthritis［J］. Practical Pharmacy And Clinical Remedies, 2010, 13（1）: 69-70（in Chinese）.
［10］李鹏. 帕米膦酸二钠的合成［J］. 中国医药工业杂志,2009,40(6):406-407.Li Peng. Preparation of Pamidronate Disodium［J］. Chinese Journal of Pharmaceuticals, 2009, 40(6): 406-407（in Chinese）.

[1]	马晶鑫;伍洲;姜申德;王红亮;武志芳. 肿瘤PET分子探针3-O-(2-¹⁸F-氟乙基)-L-多巴的合成及初步生物学评价[J]. 同位素, 2018, 31(5): 310-317.
[2]	黄钱焕;潘栋辉;徐宇平;盛洁;王彦婷;杨敏. ⁶⁸Ge/⁶⁸Ga发生器的临床应用[J]. 同位素, 2017, 30(4): 270-275.
[3]	李彦鹏;温馨;程兵;谢新立;杜晓光;韩星敏. (N-［¹⁸F］氟甲基)-胆碱的自动化合成及其生物分布研究[J]. 同位素, 2017, 30(1): 29-35.
[4]	王蕾;张晓军;周艳丽;张锦明. ¹⁸F-FDG-(OAc)₄在¹⁸F-FDG中的残留及在小鼠体内的生物分布[J]. 同位素, 2017, 30(1): 36-42.
[5]	李凤林;罗志福;樊彩云;刘子华;邓新荣. 巯基十二硼烷二钠盐的急性毒性与药代动力学研究[J]. 同位素, 2016, 29(3): 164-169.
[6]	雷晓;朱晓霞;王德才;孟志云;甘慧;顾若兰;吴卓娜;郑颖;李俭;吕明;窦桂芳. ¹²⁵I-MIL50在大鼠体内的药代动力学及生物分布[J]. 同位素, 2016, 29(2): 65-70.
[7]	韩振义;梁积新;胡骥;罗洪义;卿晶;陈玉清;李光;李洪玉. ⁶⁴Cu标记两种奥曲肽类似物的比较[J]. 同位素, 2016, 29(2): 82-88.
[8]	马欢;唐禹;杨远友;刘宁;廖家莉;杨吉军. ¹³¹I标记新型小分子肽VP2[J]. 同位素, 2016, 29(1): 1-5.
[9]	彭程;崔孟超;梁志刚;刘亭廷;张晓阳. ¹²⁵I标记的二噻吩查尔酮类Aβ斑块显像剂的制备与生物评价[J]. 同位素, 2015, 28(4): 253-258.
[10]	张锦明;张晓军;黄德晖;王卉;刘健;田嘉禾. 多发性硬化症显像剂¹¹C-CIC的合成[J]. 同位素, 2015, 28(4): 259-264.
[11]	李洪玉;梁积新;杨春慧;罗洪义;庄玲;陈阳;孙桂全;郑德强. ⁹⁹Tc^m标记DPZM类右旋糖苷衍生物的淋巴结摄取[J]. 同位素, 2014, 27(3): 162-169.
[12]	马秀凤;张君丽;李洪玉;梁积新;杨云;杨春慧;杜进. ¹⁷⁷Lu标记单克隆抗体Rituximab[J]. 同位素, 2014, 27(2): 98-103.
[13]	李贵平;黄宝丹;杜丽;韩彦江;张辉;黄凯;郑文莉. 新型肺癌小分子多肽的¹³¹I标记及其在小鼠体内的生物分布[J]. 同位素, 2014, 27(2): 104-108.
[14]	李凤林;罗志福;邓新荣;樊彩云;刘子华;吴猛. 分光光度法测量生物组织中BPA含量[J]. 同位素, 2013, 26(3): 163-169.
[15]	彭程;牟甜甜;赵祚全;马云川;张现忠. ¹⁸F标记哒嗪酮类似物的制备及其在小鼠体内的生物分布[J]. 同位素, 2013, 26(1): 23-28.